Edit
Genetron Holdings Limited（Genetron Health）
http://us.genetronhealth.com/en/aboutus.html?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 02.09.2022
Probably Closed
Genetron Holdings Limited (“Genetron Health” or the “Company”) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care.
Location: China, Guangdong Province, Beijing
Employees: 1001-5000
Total raised: $71M
Founded date: 2013
Investors 2
| Date | Name | Website |
| - | Emerging T... | etpvc.com |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.11.2019 | - | $71M | Vivo Capit... |
Mentions in press and media 12
| Date | Title | Description |
| 02.09.2022 | Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee | BEIJING, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profi... |
| 10.01.2022 | Genetron : Health Reiterates Full Year 2021 Revenue Guidance - Form 6-K | Genetron Health Reiterates Full Year 2021 Revenue Guidance BEIJING, January 10, 2022 - Genetron Holdings Limited ("Genetron Health" or the "Company", Nasdaq: GTH), a leading precision oncology platform company in China t... |
| 10.01.2022 | Genetron Health Reiterates Full Year 2021 Revenue Guidance | BEIJING, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early can... |
| 30.11.2021 | Genetron : 3Q21 Presentation | Genetron Holdings Limited (Nasdaq: GTH) 3Q 2021 Financial Results November 2021 Disclaimer The following presentation has been prepared by Genetron Holdings Limited ("Genetron Health" or the "Company") solely for informa... |
| 15.11.2021 | Genetron Health Announces Publication of Enhanced Variant Caller Performance Data in Briefings in Bioinformatics | BEIJING, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer scree... |
| 28.10.2021 | Genetron Health's Liver Cancer Screening Results and Technology Findings Included in the Chinese Journal of Hepatology | Innovative Technology of HCCscreen™ and Leading Prospective Data Well-Recognized by Expert Consensus BEIJING, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precisio... |
| 28.10.2021 | Genetron Health's Liver Cancer Screening Results and Technology Findings Included in the Chinese Journal of Hepatology | BEIJING, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer scre... |
| 25.03.2021 | GENETRON HOLDINGS LIMITED Genetron : Q4 Presentation Slides | Disclaimer The following presentation has been prepared by Genetron Holdings Limited ("Genetron Health" or the "Company") solely for informational purposes and should not be construed to be, directly or indirectly, in wh... |
| 24.03.2021 | Genetron Health Releases New Data Results of HCCscreen™ for Liver Cancer Early Screening in China | BEIJING--(BUSINESS WIRE)--Mar 24, 2021-- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screenin... |
| 21.11.2019 | Chinese gene testing firm Genetron snags $71m from Vivo Capital, others | Premium Beijing-based Genetron, that employs gene detection for cancer treatment, has completed a new funding round at over 500 million yuan ($71 million), per its announcement. Continue reading this story with a subscription to DealStreetA... |
Show more